MetaCap

MetaVia (MTVA) vs Alaunos Therapeutics (TCRT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alaunos Therapeutics is the larger company by market cap ($7.0 million vs $6.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MTVA-30.82%TCRT+98.07%
+289%+121%-46%
Oct 7, 20261 yearNov 20, 2026
MTVA-28.37%TCRT+111.25%
+248%+103%-42%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MTVA versus TCRT key metrics
MetricMTVATCRT
Share price$1.01$1.66
Market cap$6.81M$6.99M
1-day change-7.34%+3.75%
EPS (TTM)$-2.78$-1.76
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$5.00K
Revenue growth (YoY)—-50.00%
Net income (latest FY)$-12.97M$-4.18M
Operating margin—-84500.00%
Net margin—-83520.00%
52-week high$13.42$4.50
52-week low$0.966$0.72
Distance from 52-week high-92.47%-63.11%
Analyst consensusnone—
Avg. price target upside+1813.86%—
Average volume113.44K7.56M
Shares outstanding6.74M4.21M
Employees81
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About MetaVia

MTVA stock →

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

About Alaunos Therapeutics

TCRT stock →

Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs.

Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees

MTVA vs TCRT FAQ

Which is bigger, MetaVia or Alaunos Therapeutics?

Alaunos Therapeutics (TCRT) is larger, with a market capitalization of $6.99M compared with $6.81M for MetaVia (MTVA).

Are MetaVia and Alaunos Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons